


## EXHIBIT A


**Claims Chart Showing Descriptive Support in  
U.S. Provisional Patent Application Serial No. 60/441,391 for the claims of U.S. Patent  
Application Serial No. 10/542,501.**

Pending Claims of U.S. Patent Application Serial No. 10/542,501 filed 01-15-2004	Descriptive Support in US Provisional Application Serial No. 60/441,391 filed 01-16- 2003
<p>1. A method for treating bladder disease in a subject, said method comprising: administering intravesically to a subject a pharmaceutical composition comprising a therapeutic amount of a compound selected from the group consisting of: (1) a compound having the formula</p> <div data-bbox="207 810 800 1045" data-label="Chemical-Block"> </div> <p>wherein Q is a group of the formula: —CH<sub>2</sub>—CH<sub>2</sub>— , —CH=CH— or</p> <div data-bbox="321 1220 505 1329" data-label="Chemical-Block"> </div> <p>R and R<sup>1</sup> are each independently C<sub>1</sub>-C<sub>4</sub>-alkyl, R<sub>1</sub> is thienyl, phenyl, cyclopentyl or cyclohexyl and X<sup>-</sup> is a physiologically acceptable anion;</p> <p>(2) a compound having the formula</p>	<p>Discloses a method of treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of: (1) a compound having the formula</p> <div data-bbox="828 810 1421 1045" data-label="Chemical-Block"> </div> <p>wherein Q is a group having the formula: —CH<sub>2</sub>—CH<sub>2</sub>— , —CH=CH— or</p> <div data-bbox="948 1220 1131 1329" data-label="Chemical-Block"> </div> <p>R and R<sup>1</sup> are each independently C<sub>1</sub>-C<sub>4</sub>-alkyl, R<sub>1</sub> is thienyl, phenyl, cyclopentyl or cyclohexyl and X<sup>-</sup> is a physiologically acceptable anion; (page 6, lines 13-25; page 7, lines 1-2)</p> <p>(2) a compound having the formula:</p>

**Pending Claims of U.S. Patent Application  
Serial No. 10/542,501 filed 01-15-2004**


wherein  $\text{X}^-$  is a physiologically acceptable ion;

(3) a compound having the formula




wherein  $\text{X}^-$  is a physiologically acceptable ion;

(4) a compound having the formula




wherein  $\text{R}_1$  is 2-thienyl or cyclopentyl, and A is 3 $\alpha$ -(6,7-dehydro)-tropanyl methobromide, 3 $\beta$ -tropanyl methobromide, or 3 $\alpha$ -(N-isopropyl)-nortropanyl methobromide;

**Descriptive Support in US Provisional  
Application Serial No. 60/441,391 filed 01-16-  
2003**


wherein  $\text{X}^-$  is a physiologically acceptable ion;  
(page 7, lines 2-8)

(3) a compound having the formula



wherein  $\text{X}^-$  is a physiologically acceptable ion;  
(page 7, lines 8-16)


(4) a compound having the formula



wherein  $\text{R}_1$  is 2-thienyl or cyclopentyl, and A is 3 $\alpha$ -(6,7-dehydro)-tropanyl methobromide, 3 $\beta$ -tropanyl methobromide, or 3 $\alpha$ -(N-isopropyl)-nortropanyl methobromide; (page 7, lines 16-17; page 8, lines 1-7)


**Pending Claims of U.S. Patent Application  
Serial No. 10/542,501 filed 01-15-2004**

(5) a compound having the formula




wherein R is an optionally halo- or hydroxyl-substituted C<sub>1-4</sub> alkyl group, R<sup>1</sup> is a C<sub>1-4</sub> alkyl group, or R and R<sup>1</sup> together form a C<sub>4-6</sub> alkylene group; X<sup>-</sup> is a physiologically acceptable anion, and R<sub>1</sub> is H, OH, CH<sub>2</sub>OH, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy;

(6) a compound having the formula



wherein R is an optionally halo- or hydroxyl-substituted C<sub>1-4</sub> -alkyl group, R<sup>1</sup> is a C<sub>1-4</sub> -alkyl group, or R and R<sup>1</sup> together form a C<sub>4-6</sub> -alkylene group, X<sup>-</sup> is a physiologically acceptable anion and R<sub>1</sub> is H, OH, CH<sub>3</sub>, CH<sub>2</sub>OH, C<sub>1-4</sub> -alkyl, or C<sub>1-4</sub> -alkoxy;

(7) a compound having the formula




;

(8) a compound having the formula


**Descriptive Support in US Provisional  
Application Serial No. 60/441,391 filed 01-16-  
2003**

(5) a compound having the formula




wherein R is an optionally halo- or hydroxyl-substituted C<sub>1-4</sub> alkyl group, R<sup>1</sup> is a C<sub>1-4</sub> alkyl group, or R and R<sup>1</sup> together form a C<sub>4-6</sub> alkylene group; X<sup>-</sup> is a physiologically acceptable anion, and R<sub>1</sub> is H, OH, CH<sub>2</sub>OH, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy; (page 8, lines 7-15)

(6) a compound having the formula



wherein R is an optionally halo- or hydroxyl-substituted C<sub>1-4</sub> -alkyl group, R<sup>1</sup> is a C<sub>1-4</sub> -alkyl group, or R and R<sup>1</sup> together form a C<sub>4-6</sub> -alkylene group, X<sup>-</sup> is a physiologically acceptable anion and R<sub>1</sub> is H, OH, CH<sub>3</sub>, CH<sub>2</sub>OH, C<sub>1-4</sub> -alkyl, or C<sub>1-4</sub> -alkoxy; (page 8, lines 15-20; page 9, lines 1-5)







(7) a compound having the formula









;



(page 9, lines 5-7)

(8) a compound having the formula

Pending Claims of U.S. Patent Application Serial No. 10/542,501 filed 01-15-2004	Descriptive Support in US Provisional Application Serial No. 60/441,391 filed 01-16- 2003
<p>(H<sub>3</sub>C)<sub>2</sub>HC-N<sup>+</sup>CH<sub>3</sub></p>  <p>;</p> <p>and (9) a compound having the formula</p>  <p>wherein X<sup>-</sup> is a physiologically acceptable anion.</p>	<p>(H<sub>3</sub>C)<sub>2</sub>HC-N<sup>+</sup>CH<sub>3</sub></p>  <p>;</p> <p>(page 9, lines 5-7)</p> <p>and (9) a compound having the formula</p>  <p>wherein X<sup>-</sup> is a physiologically acceptable anion. (page 9, line 13; page 10, lines 1-5).</p> <p>Discloses that the preferred route of administration is intravesical (page 16, line 16)</p>
<p>2. The method according to claim 1, wherein the compound has the formula</p>  <p>wherein Q is a group of the formula</p>	<p>Discloses a method of treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of</p>  <p>wherein Q is a group of the formula</p>

<b>Pending Claims of U.S. Patent Application Serial No. 10/542,501 filed 01-15-2004</b>	<b>Descriptive Support in US Provisional Application Serial No. 60/441,391 filed 01-16- 2003</b>
<p>—CH<sub>2</sub>—CH<sub>2</sub>— , —CH=CH— or</p>  <p>R and R<sup>1</sup> are each independently C<sub>1-4</sub>-alkyl, R<sub>1</sub> is thienyl, phenyl, cyclopentyl or cyclohexyl, and X<sup>-</sup> is a physiologically acceptable anion.</p>	<p>—CH<sub>2</sub>—CH<sub>2</sub>— , —CH=CH— or</p>  <p>R and R<sup>1</sup> are each independently C<sub>1</sub>-C<sub>4</sub>-alkyl, R<sub>1</sub> is thienyl, phenyl, cyclopentyl or cyclohexyl and X<sup>-</sup> is a physiologically acceptable anion. (page 6, lines 13-25; page 7, lines 1-2)</p>
<p>3. The method according to claim 2, wherein R is CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, n-C<sub>3</sub>H<sub>7</sub>, or i-C<sub>3</sub>H<sub>7</sub> and R<sup>1</sup> is CH<sub>3</sub>.</p>	<p>Discloses a method of treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of:</p>  <p>(page 6, lines 13-19)</p> <p>Discloses that R and R<sup>1</sup> are each independently C<sub>1</sub>-C<sub>4</sub>-alkyl; (page 7, lines 1-2)</p> <p>Discloses that examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl (page 20, lines 8-10).</p>
<p>4. The method according to claim 3, wherein R<sub>1</sub> is thienyl;</p>	<p>Discloses a method of treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of:</p>  <p>(page 6, lines 13-19)</p>

Pending Claims of U.S. Patent Application Serial No. 10/542,501 filed 01-15-2004	Descriptive Support in US Provisional Application Serial No. 60/441,391 filed 01-16- 2003
	Discloses that R and R <sup>1</sup> are each independently C <sub>1</sub> -C <sub>4</sub> -alkyl; (page 7, lines 1-2)  Discloses that R <sub>1</sub> is thienyl. (page 7, lines 1-2)
5. The method according to claim 2, wherein X <sup>-</sup> is Br <sup>-</sup> or CH <sub>3</sub> SO <sub>3</sub>	Discloses that pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compounds formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic. . . and salts prepared from organic acids such as . . . methanesulfonic ... (page 20, lines 23-32)
6. The method according to claim 1, wherein the compound has the formula   wherein X <sup>-</sup> is a physiologically acceptable ion.	Discloses a method of treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of:   wherein X <sup>-</sup> is a physiologically acceptable ion. (page 6, lines 13-16; page 7, lines 3-8)
22. The method according to claim 1, wherein the compound has the formula	Discloses a method of treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of

Pending Claims of U.S. Patent Application Serial No. 10/542,501 filed 01-15-2004	Descriptive Support in US Provisional Application Serial No. 60/441,391 filed 01-16- 2003
 <p>wherein X<sup>-</sup> is a physiologically acceptable anion.</p>	 <p>wherein X<sup>-</sup> is a physiologically acceptable anion. (page 9, line 13; page 10, lines 1-5).</p>
<p>23. The method according to claim 22, wherein X<sup>-</sup> is a bromide.</p>	<p>Discloses that pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compounds formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic. . . (page 20, lines 23-27)</p>
<p>24. The method according to claim 1, wherein the pharmaceutical composition is formulated to have a prolonged duration of action.</p>	<p>Discloses that the pharmaceutical composition is formulated to have a prolonged duration of action. (page 19, lines 8-10)</p>
<p>25. The method according to claim 24, wherein the prolonged duration of action is at least about three weeks.</p>	<p>Discloses that the prolonged duration of action is at least about three weeks. (page 19, lines 14-17)</p>
<p>26. The method according to claim 1, wherein the pharmaceutical composition further comprises an additive selected from the group consisting of carboxymethyl celluloses, glycosaminoglycans, pentosan polysulfate, and heparin.</p>	<p>Discloses that the pharmaceutical composition further comprises an additive selected from the group consisting of carboxymethyl celluloses, glycosaminoglycans, pentosan polysulfate, and heparin. (page 16, lines 30-34; page 17, lines 1-3).</p>
<p>27. The method according to claim 1, wherein the subject has a condition selected from the group consisting of urge incontinence, cystitis, bladder dysfunction of multiple sclerosis, benign prostatic hyperplasia, myelomeningocele, spinal cord injury, dementia where antimuscarinic medications are contraindicated, parkinsonism, and inability to tolerate systemic effects of antimuscarinic medications.</p>	<p>Discloses that the subject has a condition selected from the group consisting of urge incontinence, cystitis, bladder dysfunction of multiple sclerosis, benign prostatic hyperplasia, myelomeningocele, spinal cord injury, dementia where antimuscarinic medications are contraindicated, parkinsonism, and inability to tolerate systemic effects of antimuscarinic medications. (page 16, lines 19-29)</p>